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indirect costs (versus 0) and the probability that patients with positive costs spent 
more than a4000 (versus less than a4000). RESULTS: Out of the 3494 questionnaires 
mailed 1189 (34.0%) were returned and fully completed. The mean age of respondents 
was 53.1 years (SD 8.6); 85.4% were women and the mean RA duration was 14.7 
years (SD 9.7). At the time of the survey, 49.9% of respondents were employed, 32.7% 
declared being on RA work disability perceiving pension invalidity. A total of 45.3% 
of employed patients had at least one sick leave over the past 6 months, with on 
average a cumulative duration of 11.6 days over. The average annual estimated indi-
rect cost was a3210 (74.4% RA-related work disability and 25.6% due to RA sick 
leaves). The three main risk factors associated with higher costs were: failure of at 
least one biotherapy (Odds Ratio-OR  4.8), RA poor functional status (severe HAQ 
versus mild HAQ, OR  3.8) and on-going treatment (disease-modifying antirheumatic 
drugs versus etanercept, OR  3.5). A high level of education is protective (OR  0.6). 
CONCLUSIONS: Pursuing preservation of functional status by treating patients 
earlier before irreversible joint damages could both improve patients’ work conditions 
and lead to potential savings for the Health Insurance.
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OBJECTIVES: Rituximab and inﬂiximab are biologic disease modifying anti-
 rheumatic drugs (DMARDS) used to treat rheumatoid arthritis (RA). Rituximab is 
re-dosed when signs and symptoms return, but inﬂiximab has ﬁxed dosing intervals. 
This 3-centre observational study was to determine the secondary care resource and 
patient time implications of this difference. METHODS: Medical records of 44 
patients with RA, treated with inﬂiximab (n  26) or at least 2 courses of rituximab 
(n  18) were reviewed retrospectively to determine mean time between end of 1st 
rituximab course and start of the 2nd, and numbers of visits and investigations for 
both drugs. Staff and patient time required for drug administration was measured 
prospectively by direct observation of 25 patients receiving inﬂiximab (n  13) or 
rituximab (n  12). RESULTS: Mean time between 1st and 2nd courses of rituximab 
was 43 weeks (range 15–84). During this time a mean of 6.9 (range 4–8) inﬂiximab 
infusions was administered. Rituximab-treated patients required 2 visits for drug 
administration during this time, vs. inﬂiximab 6.9 visits. Each visit required a mean 
of 87.2 minutes of staff time for rituximab patients vs. 46.0 minutes for inﬂiximab. 
Total staff time per patient over 43 weeks was 2.9 hours for rituximab vs. 5.3 hours 
for inﬂiximab. Mean total patient time in the unit per 43 weeks was 14.1 hours for 
rituximab vs. 25.3 hours for inﬂiximab. CONCLUSIONS: Although rituximab 
requires almost twice as much staff time per visit for its administration as inﬂiximab, 
it is administered less often so staff time required over a whole course is less for 
rituximab than inﬂiximab. An even greater difference was seen for patient time spent 
on the unit for drug administration. This study demonstrates beneﬁts from rituximab 
in terms of patient convenience and staff efﬁciency, which can inform NHS planning 
of service delivery and quality standards for patients with RA.
PMS64
ANALYSIS OF HOSPITAL EVENTS MEANING IATROGENICITY, 
ANHEMIA
Vainchtock A1, Kosa M2, Diazaraque R3, Lamarsalle L1, Duru G4
1HEVA Health Evaluation, Lyon, France, 2PFIZER FRANCE, Paris, France, 3PFIZER, Walton 
Oaks, UK, 4Université Caude Bernard, Lyon, France
OBJECTIVES: Anaemia is prevalent among old individuals. Iron deﬁciency due to 
chronic gastrointestinal loss is a frequent cause. Non-steroidal anti-inﬂammatory 
drugs (NSAIDs) are a major cause of bleeding among osteoarthritis (OA) patients. 
Analysis of Hospital Events Meaning IAtrogenicity (ANHEMIA) study aims at assess-
ing the demographic characteristics of anaemia in french OA patients and its impact 
on hospital length of stay (LOS). METHODS: Programme de Médicalisation des Sys-
tèmes d’Information (PMSI) database covers french hospital activity and is used by 
Health Authorities as resources use indicators for allocating and forecasting medical 
budget. Its Use to assess the epidemiological and economic burden of illness is recom-
mended. Cross-linkage through the ICD-10 diagnosis codes allowed the identiﬁcation 
of hospital stays with a main diagnosis of osteoarthritis (OA) and Among these, 
2 subpopulations according to the existence or absence of iron-deﬁciency anaemia 
(AN or AN-). ICD-10 diagnosis cancers were excluded. Four groups were established 
for analysis: OAAN-, OAAN in either private or public hospitals (PrH, PuH). 
RESULTS: All the groups analysis showed a higher percentage of women (p  0.001): 
2 out of every 3 patients. In PuH, mean age of OAAN patients was 73.5 years vs. 
65.3 for OAAN- patients, in PrH: 69.0 years (OAAN) vs. 58.3 (OAAN-). 
Overall, OAAN patients were signiﬁcantly older than 65 compared to OAAN- 
patients: 88.1% vs. 68.7% (p  0.001) both in PrH or PuH. Compared to OAAN- 
patients, OAAN patients had a longer LOS: 2.58 days in PuH, 2.49 days in PrH 
for matched DRG. The increase in LOS was accountable for substantial extra costs: 
a791,504 for PuH and a760,080 for PrH for the year 2006. CONCLUSIONS: 
Anaemia, is an important driver for extra-costs in hospitalized OA population. Since 
this population is likely to grow in the forthcoming years, every effort to reduce its 
incidence of anaemia should be considered.
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OBJECTIVES: Minimal Access Spinal Technologies (MAST TM) potentially allows 
surgeons to treat back pain and disability with the least amount of interruption while 
achieving the same surgical objectives as open surgeries. This single center resource 
use utilization study was designed to assess difference between MAST TM and open 
surgery in hospital length of stay and its associated costs from a hospital perspective. 
METHODS: This study aims at comparing the average length of hospital stay (LOS) 
of patients treated with MAST TM in the Foch hospital and the average National 
LOS of patients treated with open surgery. All patient operated with MASTTM in 
2007 in Foch hospital were retrospectively analyzed and were indirectly compared 
with patients from the National French DRG data base called PMSI. MASTTM and 
open surgery patients were matched on procedure code. Cost per hospital stay has 
been assessed with the French National Cost Study (ENC). RESULTS: In 2007, Foch 
hospital performed 250 MAST surgeries. The two main procedures were posterior 
lumbar arthrodesis (procedure code LFDA004/0; n  68) and removal of herniated 
disc (procedure code LFFA002/0; n  111). For posterior lumbar arthrodesis surgery, 
the average LOS in Foch Hospital was 5.9 days compared to 8.9 days in the national 
data base (34% decrease). For herniated disc surgery, the average LOS in Foch hospital 
was 3.4 days compared to 5.3 days in the national data base (36% decrease). In 2007, 
Foch hospital avoided 215 days of hospitalization with the MAST, representing 
between a133,000 and a141,000 (a320–a340 per day). CONCLUSIONS: By lowering 
morbidity and reducing recovery time, MAST TM reduces costs of hospital stays. The 
reduction of hospital days may off-set any additional device costs. Further prospective 
research should be considered to validate our ﬁndings; however this is one of the ﬁrst 
studies investigating systematically this subject.
MUSCULAR-SKELETAL DISORDERS – Patient-Reported Outcome Studies
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OBJECTIVES: To estimate the inﬂuence of non-compliance on the risk of fractures 
in German osteoporosis patients treated with oral bisphosphonate (oBP) therapy. 
METHODS: IMS® Disease Analyzer database was used; includes 11 million patients 
from ofﬁce-based physicians. Eligible osteoporosis patients (excluding malignant dis-
eases, any anticancer or cytostatic hormone prescription, Paget’s disease or AIDS) had 
data available q1-year before and after initiating oBP treatment (December 2004-
November 2007). Compliance was measured as Medical Possession Ratio (MPR; 
prescribed to assumed number of therapy units). MPR  80% assumed compliance. 
MPR was calculated for patients on therapy up to 2 years. Fractures were identiﬁed 
by ICD-10 codes; only fractures 3 months after initiating oBP were included. The 
inﬂuence of compliance on time to fracture was determined by Kaplan-Meier and Cox 
regression analyses. The model was adjusted for gender, age, prevalence of fractures 
1 year before index prescription, calcium/vitamin D co-prescription, continuation of 
the initial regimen after 6 months and after 1 year. RESULTS: A total of 4738 patients’ 
data were analyzed: 1365 (28.8%) with previous fractures. The total number of 
patients receiving oBP treatment was 177 (3.7%) daily, 4367 (92.2%) weekly and 
194 (4.1%) monthly. After 2 years, 14.5% (daily), 12.2% (weekly), and 9.7% 
(monthly) of patients experienced a fracture. The time to fracture was signiﬁcantly 
longer for compliant versus non-compliant patients (log rank test; p  0.013). Compli-
ance was associated with a 26% (95% CI 10–39%) decrease in the fracture rate versus 
non-compliance. Higher age (60 years) (44% increase; 95%CI 3–100%) and previ-
ous fractures (29% increase; 95%CI 5–57%) were associated with a signiﬁcantly 
higher risk of fractures. CONCLUSIONS: Patients receiving oBP therapy who are 
compliant have a decreased risk of fractures versus non-compliant patients. Older 
patients and those with fracture history are particularly at risk of fracture. These 
ﬁndings highlight the need to improve compliance to reduce the risk of osteoporosis-
associated fractures.
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OBJECTIVES: To examine the effect of medication choice between duloxetine and 
pregabalin on medication compliance outcomes as well as direct health care costs 
among patients with ﬁbromyalgia. METHODS: A retrospective cohort study design 
was used with a large US national commercial health care claims database over 
2005–2007. Fibromyalgia patients aged 18–64 who initiated (no pill coverage in the 
previous 90 days) duloxetine or pregabalin in 2006 were selected, with the ﬁrst initia-
tion date as the index date. All patients included had continuous enrollment in the 12 
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months pre- and post-index periods. Patients with diabetic peripheral neuropathic pain 
(DPNP) or depression in the 12 months pre-index period were excluded. Each patient 
was classiﬁed in the duloxetine or prebagalin cohort based on the initial agent. Pre-
bagalin cohort was constructed via propensity scoring controlling for differences in 
demographics, pre-index clinical and economic characteristics, and pre-index treat-
ment patterns. Medication compliance (i.e. medication possession ratio (MPR) and 
proportion of patients with MPRq80%) and health care costs over the 12 months 
post-index period were examined between cohorts. RESULTS: Both the duloxetine (n 
 3711) and pregabalin (n  4111) cohorts had the mean age around 50 years. Many 
duloxetine and pregabalin patients had neuropathic pain other than DPNP (69.1% 
vs. 69.1%), low back pain (61.9% vs. 62.1%), cardiovascular disease (55.1% vs. 
55.1%), hypertension (44.9% vs. 45.0%), and headache (36.0% vs. 35.3%), and used 
opioids (75% vs. 86%). Controlling for demographics, pre-index clinical and eco-
nomic characteristics, and prior medication history, duloxetine patients had signiﬁ-
cantly higher MPR (0.66 vs. 0.50, p  0.05), higher proportion of patients with 
MPRq80% (47% vs. 26%, p  0.05), and signiﬁcantly lower total health care costs 
($19,378 vs. $27,045, p  0.05) over the 12 months follow-up period than pregabalin 
patients. CONCLUSIONS: Fibromyalgia patients treated with duloxetine had signiﬁ-
cantly higher medication compliance, but signiﬁcantly lower direct health care costs 
than those on pregabalin.
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OBJECTIVES: To describe the adherence for different treatment regimens of oral 
bisphosphonates (oBP) in osteoporosis patients in Germany. METHODS: Analyses 
used IMS® Disease Analyser database (contains representative information on 
approximately 11 million patients from ofﬁce-based physicians). Osteoporosis patients 
with a history of malignant diseases, any anticancer or cytostatic hormone prescrip-
tions, Paget’s disease or AIDS were excluded. Eligible osteoporosis patients had data 
available at least 1-year before and after starting oBP treatment between Dec 2004 
and Nov 2007. Compliance was measured as Medical Possession Ratio (MPR); 
deﬁned as the ratio of prescribed to assumed number of therapy units. MPR  80% 
assumed compliance. MPR was calculated for patients on therapy for a maximum of 
2 years. RESULTS: Data from 4,738 patients were analyzed: 4147 (87.5%) women, 
4130 (87.2%) older than 60 years. A total of 177 (3.7%) received daily, 4367 (92.2%) 
weekly and 194 (4.1%) monthly oBP treatment. The mean MPR was 0.66 (daily), 
0.83 (weekly) and 0.84 (monthly) in the oBP treatment period. In total, only 51% of 
patients had an MPR  80%. Overall, 72% patients discontinued/switched oBP 
regimen during the ﬁrst year: 90.4% (daily), 71.6% (weekly) and 70.6% (monthly). 
CONCLUSIONS: The majority of patients were receiving weekly oBP therapy. Com-
pliance varied for the different treatment regimens, but was particularly poor in 
patients receiving daily oBP treatment. In addition, a high proportion of patients dis-
continued/switched oBP regimens during the ﬁrst year. This study provides further 
evidence of poor adherence in patients with osteoporosis receiving oBP therapy.
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OBJECTIVES: To reduce and validate the ADEOS questionnaire, an instrument spe-
ciﬁcally developed to evaluate treatment adherence by women with post-menopausal 
osteoporosis. METHODS: The ADEOS questionnaire has been developed with clini-
cians and patients. Before item reduction, it included 45 items covering 5 distinct 
themes related to adherence (personal characteristics, beliefs, perceptions, behaviour 
and information received). It was included for ﬁnalisation and validation in a cross-
sectional observational study in French general practitioners. The study sample was 
randomly divided into 2 subsamples: one for item selection, one for validation. The 
item selection procedure was performed according to the association of the items with 
a generic measure of compliance, the Morisky Medication Adherence Scale (MMAS). 
The validity of the score derived from these items was scrutinised by assessing its 
correlation with MMAS score. Its ability to separate compliant patients from non 
compliant patients according to MMAS was studied using area under receiver-operat-
ing characteristic curve (AUC). RESULTS: Five hundred sixty osteoporotic women 
were included, of whom 348 (62%) returned the ADEOS questionnaire. Patients who 
did not return the questionnaire were comparable to those who did in terms of demo-
graphics and medical parameters. The questionnaire quality of completion was very 
good, conﬁrming its good acceptability. Twelve items of the questionnaire showed a 
statistically signiﬁcant relationship (p  0.05) with the MMAS in the “item selection 
sample” (N  200) and were retained to derive the ADEOS score. In the “validation 
sample” (N  148), the ADEOS score was noticeably correlated with MMAS score 
(Spearman correlation coefﬁcient: 0.58) and showed good discriminant validity 
according to MMAS (AUC: 0.84). CONCLUSIONS: The 12-item ADEOS question-
naire is a short validated instrument speciﬁc to osteoporosis, whose score can easily 
be calculated by hand. Therefore, it might be particularly useful in daily practice to 
detect patients at risk of being poorly adherent to their osteoporosis treatment.
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OBJECTIVES: Recent anti-osteoporotic treatments are characterised by monthly or 
even yearly administration. These treatments may challenge the prescription of daily-
administered drugs. The objective of this qualitative research was to explore patients’ 
perception as well as clinicians’ views on the frequency of anti-osteoporotic treatment 
administration. METHODS: A health psychologist carried out face-to-face interviews 
with six patients treated on a daily basis and six patients treated with a monthly-
administered drug. The patients’ perception, behaviour and expectations regarding 
anti-osteoporotic treatment were assessed. Clinicians who recruited the patients, com-
prising a general practitioner and specialists, were also interviewed. Information on 
factors driving their treatment choice decision and on the importance of patients’ 
feedback and perception in their decision was collected. RESULTS: Patients perceived 
osteoporosis as a sign of premature ageing and a disease of secondary importance. 
They reported that a daily administration was not a problem per se if it did not modify 
their lifestyle. They raised concerns about lower frequency of drug administration that 
clinicians did not: the difﬁculty of remembering to take the treatment; the worry about 
the treatment being too concentrated, with the thought of a possible irregular efﬁcacy 
of the drug over the time and a harmful effect. They did not feel involved in the choice 
of treatment. Clinicians believed monthly administration to be more convenient than 
daily administration. They declared choosing the treatment according to the patient’s 
characteristics, in particular concomitant diseases, lifestyle, and dosing preference. 
CONCLUSIONS: Discrepancies exist between clinicians’ perception and reality for 
patients regarding anti-osteoporotic treatment. Consequently, possible patient-
reported outcomes approaches to improve treatment-decision would consist in 1) 
educating patients on osteoporosis, and clinicians on their patients’ perception and 
expectations, and 2) promoting shared decision-making. This is likely to contribute 
to a better persistence of the patients with regard to their treatment.
PMS71
PREDICTING CHANGES IN EQ-5D UTILITY SCORE VIA PASI OR HAQ IN 
PSORIATIC ARTHRITIS PATIENTS
Zbrozek A1, Kirkham B2, Li W1, Molta C1, Singh A1
1Wyeth Research, Philadelphia, PA, USA, 2University of New South Wales, Sydney, NSW, 
Australia
OBJECTIVES: To compare the predictive power post hoc of skin signs and physical 
function in improvement of health state utility scores in a population with active 
psoriatic arthritis (PsA). METHODS: A 12-week randomized double-blind study fol-
lowed by a 12-week open-label extension; subjects received etanercept 50 mg BIW or 
50 mg QW during the double-blind period followed by 50 mg QW during the open-
label period. Eligibility criteria included: age 18 y; stable, moderate-to-severe plaque 
psoriasis with q2 swollen/painful joints. PASI for psoriasis signs, HAQ for physical 
function, and EQ-5D were measured at baseline, Weeks 12 and 24. Logistic regression 
was used to predict the minimally clinically meaningful change in EQ-5D of at least 
0.05 (0–1.0 scale). Meaningful changes from baseline as predictors: HAQ  0.375, 
0.5; PASI  50%, 75%. RESULTS: At baseline, subjects (n  752) had a mean age 
47 y, were 63% male, and 89% white. Mean number of tender joints 19.2, and 
swollen joints 12.5. Mean durations of psoriasis and psoriatic arthritis 19 and 7 
years, respectively. Baseline scores were not signiﬁcantly different between the 2 
groups; pooled baseline (mean o s.d.) PASI  19.43 o 10.28, HAQ  0.91 o 0.69, and 
EQ-5D  0.48 o 0.32. Only PASI change from baseline at Week 12 differentiated 
treatment groups. Pooled reductions from baseline to Week 24 (LOCF) were: PASI  
75.9%, HAQ  52.0%. Proportion achieving EQ-5D (q0.05)  74.6%. HAQ changes 
from baseline were stronger predictors of pre-determined changes in EQ-5D utility 
scores than PASI changes, with HAQ change q0.375 at Week 24 being the strongest 
single change predictor (OR  4.36 (2.01–9.44)). Higher baseline HAQ scores reduced 
the odds 0.12 (0.07–0.20), and 0.19 (0.11–0.31) for minimally meaningful health 
status improvements at Weeks 12 and 24, respectively. CONCLUSIONS: Patients 
with less advanced PsA could have better odds of meaningful improvement in health 
status when treated to reduce both skin and joint morbidity.
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OBJECTIVES: To examine the relationship between disease speciﬁc-measure, Health 
Assessment Questionnaire (HAQ) disability index (DI) and the preference-based mea-
sures, Short Form-6D (SF-6D) and the EuroQoL (EQ-5D) in patients with rheumatoid 
arthritis(RA) and psoriatic arthritis (PsA). METHODS: Five hundred and four patients 
attending a rheumatology outpatient clinic with RA and PsA completed the HAQ, 
Short Form-36 and the EQ-5D before starting biologic therapy and 12 months after. 
